Lyell Immunopharma was joined by new corporate backers Lilly Asia Ventures Biosciences and Alexandria Venture Investments to bring Sonoma’s series A round to $70m.
US-based immunotherapy developer Sonoma Biotherapeutics increased its series A round to $70m on Wednesday thanks to a $30m extension involving immuno-oncology drug developer Lyell Immunopharma and pharmaceutical firm Eli Lilly.
Life sciences real estate investment trust Alexandria Real Estate Equities also took part in the round through Alexandria Venture Investments, while Eli Lilly contributed through Lilly Asia Ventures Biosciences.
Arch Venture Partners, 8VC, LifeForce Capital, Octagon Capital, the JDRF T1D Fund and additional undisclosed investors filled out the round.
Sonoma…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
